Authors: Claudia Musial, Narcyz Knap, Renata Zaucha, Paulina Bastian, Giampaolo Barone, Giosuè Lo Bosco, Fabrizio Lo-Celso, Lucyna Konieczna, Mariusz Belka, Tomasz Bączek, Antonella Marino Gammazza, Alicja Kuban-Jankowska, Francesco Cappello, Stephan Nussberger, and Magdalena Gorska-Ponikowska
Redox Biology, 8 July 2022
The authors of this study examined the influence of 2-methoxyestradiol (2-ME), a major metabolite of 17ß-estradiol (E2), on non-small cell lung cancer (NSCLC) cells as a potential therapy for patients suffering from NSCLC. The Axion BioSystems Omni was used for a cellular confluency analysis to determine the optimal cell density for A549 cells, a human lung epithelial carcinoma cell line. Moreover, the Axion BioSystems Lux3 FL was used to assess the viability of the 2-ME-treated A549 cells. All in all, the results show that 2-ME induced cell death in the lung cancer cellular model, suggesting that 2-ME can be used as a possible therapeutic adjuvant.
